SHANGHAI: Recognising the just-concluded China International Import Expo here as a globally prominent platform and a vital bridge connecting the China market with global resources, foreign companies unveiled new development strategies and announced increased investments in China during the expo.
Gnosis, the human nutrition and health division of French biotechnology leader Lesaffre Group, unveiled its new global brand image and announced its deepened global and China strategies.
The company viewed China as a key area in its global strategic layout. Its efforts will include focusing on Chinese consumers’ needs and developing corresponding solutions, as well as investing in resources tailored to China.
UK-based pharmaceutical company AstraZeneca signed a cooperation agreement with the management committee of the Qingdao High-tech Industrial Development Zone, announcing an additional investment of about US$136mil to expand the production capacity.
Since establishing its presence in Shanghai’s Pudong New Area in 1994, Roche Pharma China has been dedicated to building and continuously upgrading a comprehensive pharmaceutical value chain encompassing early-stage research, drug development, production, marketing and open collaboration.
“Roche plans to continue increasing its investment,” said Bian Xin, chief executive officer of Roche Pharma China.
Fosun Health, aiming to export Chinese medical standards and innovation capabilities, announced a collaboration between Guangzhou Fosun Chancheng Hospital and the Guangzhou Belt and Road Healthcare Center to jointly establish a medical service centre in Bangladesh. — China Daily/ANN
